Literature DB >> 9895221

Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat.

E Szabados1, G M Fischer, K Toth, B Csete, B Nemeti, K Trombitas, T Habon, D Endrei, B Sumegi.   

Abstract

The short term cardiac side-effects of AZT (3'-azido-3'-deoxythymidine, zidovudine) was studied in rats to understand the biochemical events contributing to the development of AZT-induced cardiomyopathy. Developing rats were treated with AZT (50 mg/kg/day) for 2 wk and the structural and functional changes were monitored in the cardiac muscle. AZT treatment provoked a surprisingly fast appearance of cardiac malfunctions in developing animals characterized by prolonged RR, PR and QT intervals and J point depression. Electron microscopy showed abnormal mitochondrial structure but the cardiomyocyte had normal myofibers. The AZT treatment of rats significantly increased ROS and peroxynitrite formation in heart tissues as determined by the oxidation of nonfluorescent dihydrorhodamine123 and dichlorodihydro-fluorescein diacetate (H2DCFDA) to fluorescent dyes, and induced single-strand DNA breaks. Lipid peroxidation and oxidation of cellular proteins determined from protein carbonyl content were increased as a consequence of AZT treatment. Activation of the nuclear poly-ADP-ribose polymerase and the accelerated NAD+ catabolism were also observed in AZT-treated animals. Western blot analysis showed that mono-ADP-ribosylation of glucose regulated protein (GRP78/BIP) was enhanced by AZT treatment, that process inactivates GRP78. In this way moderate decrease in the activity of respiratory complexes was detected in the heart of AZT-treated animals indicating a damaged mitochondrial energy production. There was a significant decrease in creatine phosphate concentration resulting in a decrease in creatine phosphate/creatine ratio from 2.08 to 0.58. ATP level remained close to normal but the total extractable ADP increased with 45%. The calculated free ATP/ADP ratio decreased from 340 to 94 in the heart of AZT-treated rats as a consequence of increased free ADP concentration. It was assumed that the increased free ADP in AZT-treated cardiomyocyte may help cells to compensate the defective ATP production in damaged mitochondria by activating the ATP synthesis in undamaged mitochondria. Southern blot analysis did not show decreased quantity of mtDNA deriving from AZT-treated rat hearts indicating that under our experimental conditions AZT-induced heart abnormalities are not the direct consequence of the mtDNA depletion. These data show that ROS-mediated oxidative damages, activated ADP-ribosylation reactions and accelerated NAD+ catabolism play basic roles in the development of AZT-induced cardiomyopathy in our animal model and indicated that these ROS-mediated processes can be important factors in the development of myopathy and cardiomyopathy in zidovudine-treated AIDS patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9895221     DOI: 10.1016/s0891-5849(98)00199-3

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  28 in total

1.  Prolongation of the QTc interval in HIV-infected individuals compared to the general population.

Authors:  Nico Reinsch; Marina Arendt; Marie Henrike Geisel; Christina Schulze; Volker Holzendorf; Anna Warnke; Till Neumann; Norbert H Brockmeyer; Dirk Schadendorf; Lewin Eisele; Raimund Erbel; Susanne Moebus; Karl-Heinz Jöckel; Stefan Esser
Journal:  Infection       Date:  2017-08-03       Impact factor: 3.553

2.  Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells.

Authors:  Kalyan Reddy Manda; Atrayee Banerjee; William A Banks; Nuran Ercal
Journal:  Free Radic Biol Med       Date:  2010-12-28       Impact factor: 7.376

3.  Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure.

Authors:  Orsolya Szenczi; Péter Kemecsei; Max F J Holthuijsen; Natal A W van Riel; Ger J van der Vusse; Pál Pacher; Csaba Szabó; Márk Kollai; László Ligeti; Tamás Ivanics
Journal:  Biochem Pharmacol       Date:  2005-01-12       Impact factor: 5.858

4.  Zidovudine induces downregulation of mitochondrial deoxynucleoside kinases: implications for mitochondrial toxicity of antiviral nucleoside analogs.

Authors:  Ren Sun; Staffan Eriksson; Liya Wang
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

5.  Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine.

Authors:  Smita S Ghare; Hridgandh Donde; Wei-Yang Chen; David F Barker; Leila Gobejishvilli; Craig J McClain; Shirish S Barve; Swati Joshi-Barve
Journal:  Toxicol In Vitro       Date:  2016-05-26       Impact factor: 3.500

Review 6.  Aging and HIV/AIDS: pathogenetic role of therapeutic side effects.

Authors:  Rebecca A Torres; William Lewis
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

7.  Protein nitration.

Authors:  W N Kuo; J M Kreahling; V P Shanbhag; P P Shanbhag; M Mewar
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

8.  Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.

Authors:  Kaleb C Lund; LaRae L Peterson; Kendall B Wallace
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

9.  Haem oxygenase-1 induction protects against tumour necrosis factor alpha impairment of endothelial-dependent relaxation in rat isolated pulmonary artery.

Authors:  Hany M El-Bassossy; Nabila N El-Maraghy; Hassan M El-Fayoumi; Malcolm L Watson
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

10.  Enhanced hypothalamic glucose sensing in obesity: alteration of redox signaling.

Authors:  Anne-Laure Colombani; Lionel Carneiro; Alexandre Benani; Anne Galinier; Tristan Jaillard; Thibaut Duparc; Géraldine Offer; Anne Lorsignol; Christophe Magnan; Louis Casteilla; Luc Pénicaud; Corinne Leloup
Journal:  Diabetes       Date:  2009-07-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.